Stockwatch: The Biotech Upgrade Cycle
This article was originally published in Scrip
Executive Summary
One of the positive investment attributes of the technology sector is the upgrade cycle. The continual advancements that result in faster speed, longer battery life and more features translate into consumer demand that justifies discarding last year's phone in favour of this year's model. With so many biotech companies coming to the market in the current IPO window, many are developing drugs that are upgrades of those already on the market.
You may also be interested in...
Stock Watch: Acadia And Amylyx Trial Failures Were No Shock
The overused phrase ‘pipeline in a product’ translates to ‘disappointment in a product’ when the number of indications in the pipeline contracts towards zero.
Stock Watch: COVID-19 Casts Long Shadow Over Pharma Sales
Social media-promoted vaccine hesitancy could have been a factor in the dip in established fourth-quarter vaccine sales with younger age groups targeted rather than seniors. Other drug categories may benefit from lifestyle changes prompted by the pandemic.
Stock Watch: Advanced Therapies Deliver Fourth-Quarter Flop
As drug pricing continues its ascent among hot button issues, the multi-million-dollar price tags for one-and-done advanced therapies, their justification and reimbursement all remain unaligned.